Clinical Trials Logo

Hematologic Diseases clinical trials

View clinical trials related to Hematologic Diseases.

Filter by:

NCT ID: NCT00176826 Terminated - Clinical trials for Hematologic Diseases

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Start date: September 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.

NCT ID: NCT00122980 Terminated - Clinical trials for Cerebrovascular Accident

Stroke With Transfusions Changing to Hydroxyurea

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia (SCA).

NCT ID: NCT00115336 Terminated - Clinical trials for Hematologic Diseases

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare ketorolac, a potent, non-steroidal anti-inflammatory drug (NSAID), with ibuprofen, a commonly used NSAID, for the treatment of the painful crisis of sickle cell disease (SCD).

NCT ID: NCT00058825 Terminated - Clinical trials for Hematologic Malignancies

Stem Cell Transplant for Hematologic Diseases

HIMSUM
Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

Patients are being asked to participate in this study because they have a cancer in their blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria. Any of these conditions could benefit from an allogeneic stem cell transplant using a donor that is related to the patient. Stem cells are created in the bone marrow. They grow into different types of blood cells that the patient needs, including red blood cells, white blood cells, and platelets. In a transplant, the patient's own stem cells are killed and then replaced by stem cells from the donor. Usually, patients are given very strong doses of chemotherapy prior to receiving a stem cell transplant. However, because of the patient's condition, they have a high risk of experiencing life-threatening treatment-related side-effects. Recently, some doctors have begun to use chemotherapy that does not cause as many side-effects before patients receive a transplant. This research study adds CAMPATH 1H to a low-dose chemotherapy regimen, followed by an allogeneic stem cell transplantation. We want to see whether adding CAMPATH 1H to the transplant medications helps in treating the disease. We also want to see whether there are fewer life-threatening side-effects from the treatment. CAMPATH 1H is a drug that is still being studied. CAMPATH 1H stays active in the body for a long time after patients receive it, which means it may work longer at preventing graft-versus-host-disease (GvHD) symptoms.

NCT ID: NCT00005341 Terminated - Blood Disease Clinical Trials

Blood Donation--Immune Sequelae and Recruitment

Start date: February 1992
Phase:
Study type: Observational

To determine if there were immune sequelae related to the long-term donation of blood or blood products.